BACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
BACKGROUND:Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
Authors: J V Fahy; H E Fleming; H H Wong; J T Liu; J Q Su; J Reimann; R B Fick; H A Boushey Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405
Authors: Maarten van den Berge; Ronald G Pauw; Jan G R de Monchy; Cees A van Minnen; Dirkje S Postma; Huib A M Kerstjens Journal: Chest Date: 2011-01 Impact factor: 9.410
Authors: G Brusselle; A Michils; R Louis; L Dupont; B Van de Maele; A Delobbe; C Pilette; C S Lee; S Gurdain; S Vancayzeele; P Lecomte; C Hermans; K MacDonald; M Song; I Abraham Journal: Respir Med Date: 2009-07-19 Impact factor: 3.415
Authors: Ratko Djukanović; Susan J Wilson; Monica Kraft; Nizar N Jarjour; Mark Steel; K Fan Chung; Weibin Bao; Angel Fowler-Taylor; John Matthews; William W Busse; Stephen T Holgate; John V Fahy Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405
Authors: Caroline O'Leary; Christopher Schultz; Cathal Walsh; Roisin Adams; Deborah Casey; Stephen Lane; Michael Harrison; Shane Doyle; Richard W Costello; Fionnuala King; Desmond M Murphy Journal: BMJ Open Respir Res Date: 2022-09
Authors: Neil Barnes; Andrew Menzies-Gow; Adel H Mansur; David Spencer; Fran Percival; Amr Radwan; Rob Niven Journal: J Asthma Date: 2013-05-14 Impact factor: 2.515
Authors: Ji Ho Lee; Hyun Young Lee; Chang Gyu Jung; Ga Young Ban; Yoo Seob Shin; Young Min Ye; Dong Ho Nahm; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2018-03 Impact factor: 5.764
Authors: Luis Manuel Entrenas Costa; Francisco Casas-Maldonado; José Gregorio Soto Campos; Alicia Padilla-Galo; Alberto Levy; Francisco Javier Álvarez Gutiérrez; Ana P Gómez-Bastero Fernández; Concepción Morales-García; Rocío Gallego Domínguez; Gustavo Villegas Sánchez; Luis Mateos Caballero; Antonio Pereira-Vega; Cayo García Polo; Gerardo Pérez Chica; Juan José Martín Villasclaras Journal: Pharmacoecon Open Date: 2019-09